Showing 7011-7020 of 8690 results for "".
- Lumenis Acquires Pollogen and Expands its Aesthetic Divisionhttps://practicaldermatology.com/news/lumenis-acquires-pollogen-and-expands-its-aesthetic-division/2458827/Lumenis Ltd. completed its acquisition of Pollogen Ltd., an Israeli-based medical aesthetic company that develops and manufactures advanced technologies with full-lines of clinically proven, non-invasive, anti-aging facial and body contouring treatment platforms for a spectrum of aesthetic applic
- Dr. Mandy Honored with ASDS Stegman Awardhttps://practicaldermatology.com/news/dr-mandy-honored-with-asds-stegman-award/2458828/Stephen H. Mandy, M.D., of Miami Beach, FL, was presented recently with the Samuel J. Stegman, MD, Award for Distinguished Service, the highest honor bestowed by the American Society for Dermatologic Surgery (ASDS). The Stegman Award – given to Dr. Mandy during the 2015 ASDS Annual
- FDA Approves Yervoy for Adjuvant Treatment for Fully Resected Stage III Melanomahttps://practicaldermatology.com/news/fda-approves-yervoy-for-adjuvant-treatment-for-fully-resected-stage-iii-melanoma/2458829/The FDA approved Bristol-Myers Squibb Company’s Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1mm who have undergone complete resection including total lymphadenectomy. Th
- Revance Reports Positive 6-Month Duration for RT002 in BELMONT Studyhttps://practicaldermatology.com/news/revance-reports-positive-6-month-duration-for-rt002-in-belmont-study/2458831/Revance Therapeutics, Inc., shared positive 24-week results from its multi-center BELMONT Phase 2 active comparator study of injectable RT002. The ongoing study for the treatment of glabellar lines in 268 subjects compared the safety, efficacy, and duration of effect of three doses of RT002
- Agents for Advanced Melanoma Among Prix Galien USA 2015 Award Recipientshttps://practicaldermatology.com/news/agents-for-melanoma-among-prix-galien-usa-2015-award-recipients/2458832/The Prix Galien USA 2015 Awards have been bestowed on Imbruvica® (ibrutinib) for best pharmaceutical agent, Opdivo® (nivolumab) and Keytruda® (pembrolizumab) for best biotechnology product, and the T2Candida Panel for best medical technology. 
- Imlygic Approved for Melanoma; Available in a Weekhttps://practicaldermatology.com/news/imlygic-approved-for-melanoma-available-in-a-week/2458834/The FDA has approved the Biologics License Application for Amgen’s Imlygic™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after
- Phase 3 Data Show Promius Pharma's DFD-01 Met Primary Endpoints for the Treatment of Moderate Psoriasishttps://practicaldermatology.com/news/phase-3-data-show-promius-pharmas-dfd-01-met-primary-endpoints-for-the-treatment-of-moderate-psoriasis/2458833/Findings from two Phase III studies for Promius Pharma’s investigational psoriasis drug DFD-01 show that the agent achieved the primary endpoint at day 15. The primary endpoint was the proportion of patients achieving treatment success at day 15 for both studies. In addition, both stud
- Phase 2 Psoriasis Study Shows Positive Results for Boehringer Ingelheim's Investigational Biologichttps://practicaldermatology.com/news/phase-2-psoriasis-study-shows-positive-results-for-boehringer-ingelheims-investigational-biologic/2458837/Results from a Phase II head-to-head psoriasis study show superior efficacy of Boehringer Ingelheim’s investigational biologic compound BI 655066 over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained PASI 90 with BI 655066, compared
- One Quarter of Americans Misled by Online Info: Surveyhttps://practicaldermatology.com/news/one-quarter-of-americans-misled-by-online-info-survey/2458841/One in four Americans (24 percent) say they have been misled by information about an illness or medical symptom from an unverified online source, according to a new survey from Merck Manuals. That figure increases to 30 percent among parents with children under 18 and jumps to 43 percent among mi
- Study Demonstrates Duac Significantly Reduces Inflammatory Acne Lesionshttps://practicaldermatology.com/news/study-demonstrates-duac-significantly-reduces-inflammatory-acne-lesions/2458846/Stiefel shared the findings of a head-to-head German study demonstrating that, in patients with mild-to-moderate acne vulgaris, treatment with Duac™ 3% (benzoyl peroxide 3% + clindamycin 1%) led to numerically fewer inflammatory and non-inflammatory lesions from baseline compared to treatme